Meta Platforms Inc. saw its shares climb 3.6% in pre‑market trading on Wednesday following the official launch of Muse, an autonomous artificial‑intelligence personal agent announced Tuesday evening. Muse operates on Meta’s proprietary Muse Spark model and can independently book travel, send emails, complete web forms and manage payments across iOS, Android and a dedicated web application. The launch coincides with Meta’s first tiered AI subscription offering, which provides a free tier and paid plans priced at $20 and $100 per month.

Netgear Inc. experienced an 8.9% rise in pre‑market trading after the U.S. Federal Communications Commission formally prohibited the import of all new consumer routers manufactured outside the United States, citing national‑security risks linked to foreign supply chains and cybersecurity vulnerabilities. The ban applies to new device models seeking FCC certification. Netgear benefits because it already secured a conditional FCC approval exemption that permits it to continue delivering firmware updates and support for its existing router portfolio while competitors adjust to the new restrictions. The company also reported that its enterprise segment recorded 7.7% year‑over‑year growth and achieved an all‑time‑high non‑GAAP gross margin of 54.1% in its most recent quarter.

Braze Inc., a customer‑engagement software provider, posted adjusted earnings per share of $0.19 for fiscal second quarter 2027, surpassing the analyst consensus of $0.15, and revenue of $227.2 million, beating the expected $220.23 million. However, the company forecast fiscal third‑quarter adjusted EPS of $0.13 to $0.14, a midpoint roughly 15%‑16% below the consensus estimate of $0.16. Management also noted that revenue growth slowed to 26.2% year‑over‑year in the second quarter from 30.2% in the first quarter, free‑cash‑flow margins declined sequentially, and customer growth showed signs of deceleration. Canaccord raised its price target to $37 and maintained a Buy rating, citing record free cash flow and strong billings growth.

Evommune Inc., a biotechnology firm, saw its shares drop 13.9% to $11.26 after announcing that its Phase 2b trial of the drug candidate EVO756 failed to meet both primary and secondary endpoints in adults with moderate‑to‑severe atopic dermatitis. The randomized, double‑blind, placebo‑controlled study enrolled 121 adults over a 12‑week treatment period and measured the percentage change in the Eczema Area and Severity Index score from baseline at Week 12 as the primary endpoint. The company said it will not advance EVO756 for atopic dermatitis but will continue Phase 2b development of the compound as a potential migraine‑prevention therapy.

U.S. equity futures were lower in early pre‑market trading, with S&P 500 futures down 19 points (0.3%), Nasdaq 100 futures down 134 points (0.5%) and Dow Jones futures down 206 points (0.4%) as of 06:13 ET (10:13 GMT). Oil prices rose above $100 per barrel, adding to inflation concerns that could influence the Federal Reserve’s policy outlook and potentially affect interest‑rate‑sensitive growth stocks.